#### 1 Continuous quality improvement with a two-step strategy effective for large-scale

- 2 SARS-CoV-2 screening at the Tokyo 2020 Olympic and Paralympic Games
- Short Title: Quality laboratory improvement for SARS-CoV-2 screening at mass-gathering
   sporting events
- 5
- <sup>6</sup> Hayato Miyachi <sup>1\*</sup>, Satomi Asai <sup>2</sup>, Rika Kuroki <sup>3</sup>, Kazuya Omi <sup>4</sup>, Chiaki Ikenoue <sup>5</sup>, and
- 7 Satoshi Shimada<sup>6</sup>
- <sup>1</sup> Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, 259-
- 9 1193, Japan and Faculty of Clinical Laboratory Sciences, Nitobe Bunka College, Tokyo 164-
- 10 0001 Japan; miyachi@tokai.ac.jp
- <sup>2</sup> Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, 259-
- 12 1193, Japan; sa@tokai.ac.jp
- <sup>3</sup> SRL Inc., Tokyo, 107-0052, Japan; rika.kuroki@hugp.com
- <sup>4</sup> SRL Inc., Tokyo, 107-0052, Japan; H.U. Group Research Institute G.K., Tokyo, 197-0833,
- 15 Japan; and Fujirebio Inc., Tokyo, 107-0052, Japan; kazuya.omi@hugp.com
- <sup>5</sup> Center for Field Epidemic Intelligence, Research and Professional Development, National
- 17 Institute of Infectious Diseases, Tokyo, 162-8640, Japan; i-chiaki@niid.go.jp
- <sup>6</sup> Department of Eco-Epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki
- 19 University, Nagasaki, 852–8523, Japan and Center for Emergency Preparedness and
- 20 Response, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan;
- 21 satoshishimada30@gmail.com
- 22
- 23 \*Correspondence: miyachi@tokai.ac.jp; Tel.: + 81-3-3381-0121
- 24
- 25 **Keywords:** COVID-19; Olympic Games; sporting events; mass gatherings

# 26 Abstract

27

28 The Tokyo 2020 Olympic Games (Games) were held during the height of the coronavirus 29 disease 2019 (COVID-19) pandemic. In order to detect the severe acute respiratory syndrome 30 coronavirus-2 (SARS-CoV-2) early enough to contain the spread as well as to facilitate the 31 timely arrival of athletes at their game venues, all participating athletes up to 14,000 staying 32 in the Olympic Village were screened daily for the infection. Toward this aim, a two-step 33 strategy was adopted comprising screening of self-collected saliva samples using a 34 chemiluminescence enzyme immunoassay followed by confirmatory testing using 35 polymerase chain reaction. The testing system was integrated with an information 36 management system covering all steps. To ensure the accuracy of testing results, rigorous 37 quality assurance measures and monitoring of performance/specimen quality were 38 implemented. The chronological chart analysis was implemented to monitor the holistic 39 process and to give feedback to improve the sampling. Nearly all test results for 418506 40 saliva samples were reported within 12 hours of sample collection, achieving the target mean 41 turnaround time of 150 minutes for confirmatory testing. As a result, athlete activity and 42 performance for the Games were ensured. The chronological chart confirmed that no athletes 43 were retired due to a false-positive result and no infection clusters among athletes were 44 identified. In conclusion, continuous quality improvement in the two-step strategy for the 45 large-scale screening of COVID-19 contributed to the success of the Games during the 46 pandemic. The quality practice, systems, and workflows described here may offer a model for 47 future mass-gathering sporting events during similar major infectious disease epidemics.

# 49 Introduction

50 Held in Summer 2021 following a 1-year postponement amid the coronavirus disease 51 2019 (COVID-19) pandemic, the Tokyo 2020 Games faced the challenge of surging COVID-52 19 rates, with the incidence reaching unprecedented levels both in Tokyo and globally [1]. 53 The Tokyo 2020 Infectious Diseases Control Centre organized by the Tokyo Organizing 54 Committee of the Olympic and Paralympic Games (TOCOG) played a vital role in containing 55 the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the 56 Games via the implementation of planned biosafety protocols, including frequent testing for 57 SARS-CoV-2 [2].

58 In order to detect the virus with sufficient time to contain the spread as well as to 59 facilitate the timely arrival of athletes at their game venues, all participating athletes and 60 others staying in the Olympic Village were screened daily for SARS-CoV-2 infection with a 61 two-step strategy comprising screening of self-collected saliva samples using a 62 chemiluminescence enzyme immunoassay (CLEIA) followed by confirmatory testing of 63 saliva and nasopharyngeal swab samples using polymerase chain reaction (PCR) [2,3] instead 64 of PCR screening. Although the "gold standard" of SARS-CoV-2 testing via PCR using NP 65 swab samples is accurate and reliable, results may take 24–48 h to return. Such delays may 66 lead to not only further transmission of disease but can also diminish the daily activity of 67 athletes for training and arrival at the match venue. Furthermore, it requires trained 68 professionals in full protective equipment to collect specimens one person at a time. Solutions 69 to improve the efficiency of mass-screening for SARS-CoV-2 include the replacement of NP 70 swab samples with self-collected saliva thereby eliminating specialized medical personnel 71 and allowing simultaneous parallel sample collection [3]. To monitor in real-time the 72 workflow processes of each individual test, the testing system was integrated with an 73 information management system covering all steps from specimen collection to reporting

74 results. This strategic allocation of PCR tests to cases that were CLEIA-positive or 75 inconclusive not only maintained accuracy but also significantly improved logistical 76 efficiency in administering mass screenings. Notably, PCR testing is associated with a 77 potential risk of false-positive results, which causes unnecessary withdrawal of athletes from 78 the Games. In order to ensure the COVID-19 screening test, we implemented continuous 79 quality improvement through rigorous quality assurance measures, performance/specimen 80 quality monitoring by an internal quality assessment, and a chronological chart analysis for 81 individual cases.

82

#### Material and methods 83

Patient and public involvement 84

85

86 The study's design including participants was planned and conducted under requests and the 87 endorsement of the TOCOG according to the regulation and the criteria specified by the 88 Ministry of Health, Labour, and Welfare of Japan. Up to 14,000 athletes and team officials 89 were tested daily for SARS-CoV-2 in order to detect infections early as required by the 90 TOCOG.

91

#### A two-step large-scale screening strategy 92

93 To facilitate the timely arrival of athletes at their game venues, test results had to be 94 available within a 12-hour turnaround time (TAT). For this large-scale screening, a two-step 95 strategy was adopted, instead of PCR screening [2,3]. First, quantitative antigen testing was 96 performed using a quantitative CLEIA with a fully automated instrument (Lumipulse® 97 Presto SARS-CoV-2 Ag, Fujirebio, Tokyo, Japan). The quantitative CLEIA is a high-98 throughput assay with high sensitivity, specificity, and short TAT, and can provide rapid

99 results as an initial saliva screening test. Positive or inconclusive results were confirmed 100 using a standard PCR test. If the saliva PCR showed positive results, a nasopharyngeal (NP) 101 swab was collected at the athletes' village fever clinic for confirmatory PCR testing using the 102 SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc., Kusatsu, Japan) with 103 instruments such as the QuantStudio5 (Thermo Fisher Scientific K.K., Waltham, MA, USA), 104 LightCycler 96 (Roche Molecular Systems, Inc., Pleasanton, CA), and CFX96 (Bio-Rad 105 Laboratories, Inc., Hercules, CA, USA). Symptomatic participants also underwent PCR 106 testing of NP swabs. The workflow was integrated with an information management system. Self-collected saliva was brought to the reception area by COVID-19 Liaison Officers 107 108 (CLOs). At the reception department, accreditation ID was linked with the sample ID in the 109 information management system by barcode. Radiofrequency identification (RFID, Toppan 110 Forms Inc., Tokyo, Japan) was incorporated into the information management system for 111 specimens. The laboratory information and reporting system (Neo Polaris and Fukuda System, 112 H.U. Group Research Institute G.K., Tokyo, Japan) allowed for real-time monitoring of the 113 workflow processes of each test, covering the entire process from receipt of the specimen to 114 reporting the result to CLOs in addition to recording the internal laboratory workflow (Figure 115 1).

Five laboratories coordinated the conducting of testing for various Olympic Games venues. Quantitative CLEIA and PCR tests were also performed in four laboratories outside the village, located in Kawasaki, Tokyo, Sapporo, and Iwaki.

119

120

Fig 1. Workflow Quality Monitoring. The workflow was integrated with an information
management system. Self-collected saliva was brought to the reception area by COVID-19
Liaison Officers (CLOs). The accreditation ID of personnel for the Village was linked with

radiofrequency identification and sample ID barcodes. This feedback process was used to communicate with the Tokyo Organizing Committee of the Olympic and Paralympic Games (TOCOG) about re-training of CLOs and TOCOG staff in appropriate collection techniques, including self-sampling of saliva before eating, specimen refrigeration within 24 hours of sampling, and NP swab collection, enabling real-time corrections of the process.

129

### **Rigorous quality assurance measures**

131 As the Tokyo 2020 Games were an international multi-sport event during a pandemic, 132 quality laboratory practices based on both global and regional perspectives were rigorously 133 implemented [4,5]. Actions taken were based on discussion and consensus during the 134 development of the International Organization for Standardization standard (ISO/TS 5798) 135 for SARS-CoV-2 detection using nucleic acid amplification methods [4]. To maintain the 136 expected performance of SARS-CoV-2 laboratory tests, meticulous quality assurance measures such as personnel training, competency assessments, assay performance 137 138 evaluations, and internal quality controls based on cycle threshold values, were implemented. 139 The assay performance was monitored and confirmed by a nationwide external quality 140 assessment of SARS-CoV-2 nucleic acid amplification tests in Japan [5].

141

# 142 **Results**

# **Test volume and turnaround time**

During the Games, all participating athletes up to 14,000 and others staying in the Olympic Village were screened daily for SARS-CoV-2 infection with a two-step strategy comprising screening of self-collected saliva samples using a CLEIA followed by confirmatory testing of saliva and nasopharyngeal swab samples using PCR. Using a testing

system integrated with an information management system covering all steps, from specimen collection to reporting of the results, enabled monitoring processes of each testing down to confirmatory test results to be provided. A total of 418,506 saliva samples were tested using the quantitative antigen test. Nearly all tests were reported within 12 hours of sample collection, aligning with the target of a mean TAT of 150 minutes for confirmatory tests.

153

# 154 **Continuous quality improvement**

155 Quality assurance of tests based on both global and regional perspectives was rigorously 156 implemented. To ensure the entire examination process from sample collection to the results 157 report, we developed and analyzed a chronological chart of cases with positive and 158 inconsistent results, providing a holistic overview of the testing process, confirming test 159 results, and identifying underlying problems including poor specimen quality and false-160 positive results. Inconsistent results were interpreted and judged whether reasonable as a 161 natural course of infection or suspicious test result due to a possible error in any portion of 162 the testing process.

163 Particularly, sample collection methods could impact the results; the pre-examination 164 process posed a critical challenge for mass screening. CLOs played a crucial role in 165 instructing athletes and team officials in proper self-sampling procedures. However, self-166 sampling in individual rooms had a risk of poor specimen quality due to suboptimal 167 collection and storage practices. Visual examination of specimens revealed sediments, which 168 caused nonspecific reactions, increasing rates of re-measurement, and prolonged the TAT. To 169 mitigate these nonspecific reactions due to sediments, the phosphate-buffered saline for 170 dilution was changed to a proprietary buffer. We evaluated specimen quality using amylase 171 measurement with CicaLiquid AMY (Kanto Chemical Co., Inc., Tokyo, Japan) on a fully automated analyzer (JCA-BM8040, JEOL Ltd., Tokyo, Japan). A high proportion of 172

specimens showed amylase levels under the reference range, suggesting inappropriate storageof specimens at ambient temperature.

175 In the continuous quality improvement of testing during the Games, continuous 176 monitoring was implemented to identify potential bias, which allowed real-time actionable 177 feedback to the TOCOG. We used this feedback process to communicate with TOCOG 178 regarding the re-training of CLOs and TOCOG staff in appropriate collection techniques 179 including self-sampling of saliva before eating, specimen refrigeration within 24 hours of 180 sampling, and NP swab collection. This enabled real-time corrections in the testing process. 181 As a result, the activity and performance of athletes for daily training and participation in the 182 games were ensured. The chronological chart for the individual test results enabled us to 183 confirm in real-time that there were neither infection clusters identified in athletic teams 184 inside the village or Games venues due to false-negative results, nor unnecessary withdrawal 185 of athletes from the Games due to false-positive results.

186

### 187 Limitations

188 The testing for SARS-CoV-2 detection to detect infections early was performed, according to 189 the regulation and the criteria specified by the Ministry of Health, and Labour in Japan. 190 Ideally, the quality and competence of the laboratory and the reliability of its testing service 191 would be objectively audited and endorsed by the third-party accreditation. However, in 192 Japan, laboratory accreditation under ISO 15189, Medical Laboratories – Requirements for 193 quality and competence [6], applies laboratory tests for medical use but not those for public 194 use such as for SARS-CoV-2 screening tests of participating athletes and others staying in the 195 Olympic village. Thus, the laboratory was not subjected to accreditation under ISO 15189. 196 The operation of laboratories was built and conducted, in alignment with the criteria specified

197 for the central laboratory which had been accredited under ISO 15189 and had a

responsibility for the testing for SARS-CoV-2 detection under a contract with TOCOG.

199

# 200 **Discussion**

In order to detect SARS-CoV-2 infections as early as possible and to take measures to prevent further spread, a two-step strategy was adopted to meet the large-scale screening requirements of the event. The integration of a testing system with an information management system covering all steps from specimen collection to reporting of the results enabled confirmatory test results to be provided within 12 hours, achieving our target of a mean TAT of 150 minutes for confirmatory tests. This integration enabled all athletes to keep the daily activity of training prior to the match and participate at the game match venue.

208 The accuracy of testing results can have an impact on the risk of transmission of disease. 209 False-negative results may lead to further transmission of disease. False-positive results 210 would lead to the withdrawal of the athlete from further participation in the games. 211 Considering the Tokyo 2020 Games being an international multi-sport event during a 212 pandemic, quality laboratory practices based on both global and regional perspectives were 213 rigorously implemented. In order to minimize such a risk, we implemented and maintained 214 rigorous quality assurance of the entire process of examination of daily testing for SARS-215 CoV-2. Quality assurance measures included personnel training, competency assessments, 216 assay performance evaluations, and internal quality controls based on cycle threshold values. 217 In addition to that, the pre-examination process was a critical challenge of mass screening in 218 the event. CLOs instructed athletes and team officials on how to perform self-sampling. 219 However, self-sampling in individual rooms posed a risk of poor specimen quality due to

suboptimal collection and storage. In order to monitor the quality of specimens, we adoptedvisual inspection and measurement of amylase in saliva.

222 This shows that international major sporting events could be held during major infectious 223 disease epidemics comparable to the COVID-19 pandemic without causing spikes in the case 224 numbers [7]. These results support the approach, advocated by the World Health 225 Organization, that responding to and managing the COVID-19 pandemic requires using all 226 available options, including public health and social measures, robust test-and-trace systems, 227 and vaccination [1]. During the early phase of the COVID-19 pandemic, most mass-gathering 228 sports events used PCR testing for infection control, which required an extended TAT for 229 receiving results and enforcing quarantine [8-10]. Furthermore, PCR has a potential risk of 230 false-positive results, which caused unnecessary withdrawal of athletes from the Games. Our 231 experience suggests that continuous quality improvement implemented in the two-step 232 strategy and infection control measures at the Games were successful.

The SARS-CoV-2 positivity rate among the 11,417 Olympic and 4,393 Paralympic athletes was 0.03% of the total tests conducted [11]. Notably, the chronological chart for the individual test results enabled us to confirm in real-time that there were neither infection clusters identified in athletic teams inside the village or Games venues due to false-negative results, nor unnecessary withdrawal of athletes from the Games due to false-positive results.

238

## 239 **Conclusion**

In conclusion, continuous quality improvement was implemented in the two-step strategy for large-scale COVID-19 screening and contributed to the success of international major sporting events during the pandemic. The quality practice, systems, and workflows of testing with continuous quality improvement, described in this report could serve as a model for future mass-gathering sporting events during similar major infectious disease epidemics.

245

246	Author Contributions: Conceptualization and design, H.M., S.A., R.K., K.O., C.I., and S.S.;
247	material preparation, data collection and analysis, H.M., R.K., and K.O., and S.S.; writing-
248	review and editing, H.M., S.A., C.I., and S.S. All authors commented on previous versions of
249	the manuscript. All authors read and approved the final manuscript.
250	Institutional Review Board Statement: Ethical review and approval were waived for this
251	study due to the Act on the Prevention of Infectious Diseases and Medical Care for Patients
252	with Infectious Diseases (the Infectious Diseases Control Law) in Japan.
253	Informed Consent Statement: Patient consent was waived due to the Act on the Prevention
254	of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the Infectious
255	Diseases Control Law) in Japan.
256	Data Availability Statement: The data that support the findings of this study are available
257	from the corresponding author upon reasonable request.
258	Acknowledgments: We would like to thank the Tokyo 2020 Organizing Committee. The
259	findings and conclusions in this report are those of the authors and do not necessarily
260	represent the official position of the Tokyo 2020 Organizing Committee. The Tokyo 2020
261	Organizing Committee does not endorse any commercial products or services.

# 263 **References**

- 1. World Health Organization (2020). Rolling updates on coronavirus disease (COVID-
- 265 19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus266 2019/events-as-they-happen (Accessed on 27 Nov 2023).
- Shimada S, Ikenoue C, Iwashita Y, Miyamoto T. Contributions of the Tokyo 2020
   Infectious Diseases Control Centre in curbing SARS-CoV-2 spread during the
   Olympic and Paralympic Games. Br J Sports Med. 2023;57:6-7. doi:
   10.1136/bjsports-2022-105691.
- Yokota I, Shane PY, Teshima T. Logistic advantage of two-step screening strategy for
   SARS-CoV-2 at airport quarantine. Travel Med Infect Dis. 2021;43:102127. doi:
   10.1016/j.tmaid.2021.102127.
- 4. International Organization for Standardization. ISO/TS 5798; 2022. In vitro diagnostic test systems Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods. Available from: https://www.iso.org/standard/81712.html (Accessed on 27 Nov 2023).
- 5. Asai S, Seki A, Akai Y, Tazawa H, Kakizoe H, Ravzanaaadii MA, et al. Nationwide
  external quality assessment of SARS-CoV-2 nucleic acid amplification tests in Japan.
  Int J Infect Dis. 2022;115:86-92. doi: 10.1016/j.ijid.2021.11.022.
- 282
- Zhang Y, Ai J, Bao J, Zhang W. Lessons learned from the COVID-19 control strategy
   of the XXXII Tokyo Summer Olympics and the XXIV Beijing Winter Olympics.
   Emerg Microbes Infect. 2022;11:1711-1716. doi: 10.1080/22221751.2022.2090859.
- 7. ISO 15189:2022. Medical laboratories Requirements for quality and competence
   https://www.iso.org/standard/76677.html

288	8.	Burke P. Tokyo	2020 did not a	result in increase	d COVID-19	cases in Japar	ı IOC
289		claims	citing	study.	31	Dec	2021.
290		https://www.insi	dethegames.biz/a	articles/1117299/t	okyo-2020-cc	ovid-cases-conta	ined-
291		ioc					
292	9.	Nishino T Obara	n K Nishida Y et	t al. Large-scale i	nternational v	olleyball compo	etition
293		in "bubble" unde	er the COVID-19	pandemic. Asia	Pac J Sports 1	Med Arthrosc R	ehabil
294		Technol. 202227	:9–12. doi: 10.10	016/j.asmart.2021	.12.001.		
295	10	Caniza H Forric	ol F Pangrazio (	O et al. Safety of	of internation	al professional	sports
296		competitions dur	ring the COVID	0-19 pandemic: t	he association	n football exper	ience.
297		Sports Med. 202	353:765–768. do	oi: 10.1007/s4027	9-022-01763-	3. Epub 2022 S	ep 27.
298		PMID: 36167919	)				
299	11.	. The Tokyo Orga	nising Committe	ee of the Olympi	c and Paralyn	npic Games. CO	)VID-
300		19 positive	case list.	Available fro	om: https:/	/olympics.com/t	okyo-
301		2020/en/notices/e	covid-19-positive	e- case-list (Acces	ssed on 27 No	w 2023).	

